Stephen Davis - Feb 23, 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Feb 23, 2022
Transactions value $
-$93,486
Form type
4
Date filed
2/25/2022, 04:40 PM
Previous filing
Jan 10, 2022
Next filing
Apr 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +10.9K +18.64% $0.00 69.7K Feb 23, 2022 Direct
transaction ACAD Common Stock Sale -$93.5K -3.93K -5.64% $23.80 65.7K Feb 23, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 +10.9K +50% $0.00 32.8K Feb 23, 2022 Common Stock 10.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning February 23 2022.